The Department of Medicinal Chemistry is proud to share that our very own Dr. Daniel Harki has been named a Fellow of the Royal Society of Chemistry. Congratulations are in order! ?? ?? ?? ?? Read more:
Midwest AViDD Center
生物技术研究
Minneapolis，Minnesota 279 位关注者
Our mission at the Midwest AViDD Center is to develop the next generation of antiviral drugs for pandemic-level viruses.
关于我们
Our mission at the Midwest Antiviral Drug Discovery (AViDD) Center is to quickly develop the next generation of antiviral drugs for pandemic-level viruses, including SARS-CoV-2, Ebola, Lassa and Zika viruses. The Center is part of a network of nine national centers established by the National Institute of Allergy and Infectious Diseases (NIAID). The Center is a key part of an overall initiative to bring expertise across disciplines to discover effective responses to pandemics, life-threatening infections, and antimicrobial resistance through basic, translational and clinical research. Embedded in an academic setting, we utilize a balance of innovative and proven approaches and technologies to develop inhibitors to established druggable processes and less conventional but equally essential viral processes. We aim to deliver novel inhibitors that can be developed into effective orally available drugs that potently and safely suppress virus replication and help prevent infections and adverse clinical outcomes including death.
- 网站
-
https://midwestavidd.umn.edu/
Midwest AViDD Center的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Minneapolis，Minnesota
- 类型
- 教育机构
- 创立
- 2022
地点
-
主要
获取路线
321 Church St SE
US，Minnesota，Minneapolis，55455
Midwest AViDD Center员工
-
Peter Dosa
Associate Program Director at Institute for Therapeutics Discovery & Development, University of Minnesota
-
Dorian Bagni
Academic Research - A.I. in Drug Discovery
-
Joseph Rollie
Researcher with the Biochemistry, Molecular Biology, and Biophysics Department at the University of Minnesota.
动态
-
A new study by the Midwest AViDD Center reveals that Sudan ebolavirus glycoprotein binds to the human NPC1 receptor approximately 9 times more strongly than Ebola virus glycoprotein. #Ebola #sudan #filovirus University of Minnesota Medical School https://lnkd.in/g9Wtf6XT
-
Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50%, posing a serious threat to global health and safety. To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed?the first nanobody-based inhibitors targeting the Ebola virus. #nanobody #ebola #marburg #AViDD University of Minnesota Medical School https://lnkd.in/gcJcXf7j
-
Researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center introduced Nanosota-9, a nanobody capable of neutralizing a broad range of SARS-CoV-2 variants. #nanobody #AViDD #antiviral #drugdiscovery University of Minnesota Medical School https://lnkd.in/gBKrfu86
-
Midwest AViDD Center Researchers Recognized in Clarivate’s 2024 Highly Cited Researchers List https://lnkd.in/gdN7_sda
-
-
Come join our last Midwest AViDD Center lecture for 2024.
此处无法显示此内容
在领英 APP 中访问此内容等
-
Midwest AViDD Center Speaker: Michael Kay, MD, PhD. Department of Biochemistry, School of Medicine, University of Utah Seminar in 1-125 CCRB:?D-peptide Inhibitors: Empowering Nature’s Fragile Warriors Attendance in person is preferred. Zoom link:?https://lnkd.in/gDaRU-RW https://lnkd.in/d_yGe5gu
此处无法显示此内容
在领英 APP 中访问此内容等
-
Scientists at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed a new strategy to keep antibody treatments effective against rapidly changing COVID-19 variants like Omicron. As the virus evolves, older treatments lose their potency. To address this, the team is using nanobodies – tiny antibodies from alpacas and llamas – and phages, which are viruses that attack bacteria, to stay ahead of the virus’s mutations. READ MORE BELOW. #omicron #antibody #viralvariants https://lnkd.in/gasN2b_z